RegulatoryOfficial

AIFA: Emend 125 mg + 80 mg capsules to leave Italian market on 30 November

🇮🇹 AIFA · Mon 16 Nov 2026

MSD Italia says Merck Sharp & Dohme is permanently ending EU/EEA marketing of Emend (aprepitant) for commercial reasons, not because of safety, efficacy or quality concerns.

The Italian Medicines Agency (AIFA) announced on 16 November 2026 that Emend (aprepitant) will be permanently withdrawn from sale. MSD Italia S.r.l., the local representative of Merck Sharp & Dohme B.V., told AIFA and other European regulators that marketing will cease across the European Union and European Economic Area.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.

More Regulatory All →